Akiko Arimura

Ms. Akiko Arimura


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
KMKimihisa Mizoguchi
Kimihisa Mizoguchi
HKHitomi Kawaji
Hitomi Kawaji
MKMasaya Kai
Masaya Kai
TMTakafumi Morisaki Morisaki
Takafumi Morisaki Morisaki
SHSaori Hayashi
Saori Hayashi
MKMakoto Kubo
Makoto Kubo
Tumor-infiltrating lymphocytes in the tumor microenvironment are important in the treatment of triple-negative breast cancer (TNBC). Cytotoxic T cells produce cytokines and cytotoxic factors, such as perforin and granzyme, which induce apoptosis by damaging target cells. To identify biomarkers of these cells, we investigated granzyme B (GZMB) in the tumor microenvironment as a biomarker of treatment response and prognosis in 230 patients with primary TNBC who underwent surgery without preoperative chemotherapy between January 2004 and December 2014. Programmed cell death ligand 1 (PD-L1) positivity was defined as a composite positive score ≥10 based on the PD-L1 immunostaining of tumor cells and immune cells. GZMB-high was defined as positivity in ≥1% of tumor-infiltrating lymphocytes (TILs). Among the 230 TNBC patients, 117 (50.9%) had CD8-positive infiltrating tumors. In the PD-L1-positive group, a Kaplan–Meier analysis showed that GZMB-high TNBC patients had better recurrence-free survival (RFS) and overall survival (OS) than GZMB-low patients and that OS was significantly longer (RFS: p = 0.0220, OS: p = 0.0254). A multivariate analysis also showed significantly better OS in PD-L1- and GZMB-high patients (hazard ratio: 0.25 (95% IC: 0.07–0.88), p = 0.03). Our findings indicate that GZMB is a useful prognostic biomarker in PD-L1-positive TNBC patients.

18 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AAAkiko Arimura
Akiko Arimura
KSKazuko Sakai
Kazuko Sakai
KKKazuhisa Kaneshiro
Kazuhisa Kaneshiro
TMTakafumi Morisaki Morisaki
Takafumi Morisaki Morisaki
SHSaori Hayashi
Saori Hayashi
MKMakoto Kubo
Makoto Kubo
Precise biomarkers for predicting the therapeutic efficacy of molecularly targeted drugs are limited at the protein level; thus, it has been important to broadly scrutinize individual cancer driver gene mutations for effective cancer treatments. Multiplex cancer genome profiling can comprehensively identify gene mutations that are therapeutic targets using next-generation sequencing (NGS). In addition, circulating tumor DNA (ctDNA) is a DNA fragment released into the blood by tumor cell-derived cell death or apoptosis. Liquid biopsy with ctDNA is a novel clinical test for identifying genetic mutations in an entire population noninvasively, in real-time, and heterogeneously. Although there are several reports on ctDNA, fewer have evaluated ctDNA with NGS before an initial treatment for breast cancer patients. Therefore, we examined whether analyzing tumor-associated gene mutations in primary breast cancer based on ctDNA could serve as a biomarker for prognosis and optimal treatment selection. Ninety-five primary breast cancer patients treated at our department from January 2017 to October 2020 were included. Pretreatment plasma samples were subjected to NGS analysis of ctDNA, and correlations with patients’ clinicopathological characteristics were evaluated. Fifty-nine (62.1%) patients were positive for ctDNA. ctDNA tended to be positive in hormone receptor-negative, and TP53 (34%), BRCA1 (20%), and BRCA2 (17%) gene mutations were more frequent. Regarding recurrence-free survival, the prognosis was poor in the TP53 and/or BRCA1 mutation-positive groups, especially in triple-negative breast cancer (TNBC) patients. In conclusion, the results of this study indicate that ctDNA with liquid biopsy could identify the poor prognosis group before treatment among TNBC patients and for those for whom optimal treatment selection is desirable; additionally, optimal treatment could be selected according to the ctDNA analysis results.

5 January 2021 in Surgical Case Reports
Verified
Journal Article
Open access
PDF file
AAAkiko Arimura
Akiko Arimura
THTakuma Hashimoto
Takuma Hashimoto
MKMasaya Kai
Masaya Kai
TNTetsuzo Nakayama
Tetsuzo Nakayama
MYMai Yamada
Mai Yamada
MNMasafumi Nakamura
Masafumi Nakamura
Background: Erythropoietic protoporphyria (EPP) is a rare disorder of heme synthesis. Patients with EPP mainly show symptoms of photosensitivity, but approximately 20% of EPPs are associated with the liver-related complications. We report a case of breast cancer in a 48-year-old female patient with EPP in whom meticulous perioperative management was required in order to avoid complications resulting from this disease. Case presentation: The patient was diagnosed with EPP at the age of 33 and had a rich family history of the disease. For right breast cancer initially considered as TisN0M0 (Stage 0), the right mastectomy and sentinel lymph node biopsy were performed, while the final stage was pT1bN0M0, pStage I. In the perioperative period, we limited the drug use and monitored light wavelength measurements. Besides, we covered surgical lights, headlights, and laryngoscope’s light with a special polyimide film that filtered the wavelength of light causing dermal photosensitivity. After the surgery, any emerging complications were closely monitored. Conclusions: The surgery, internal medicine, anesthesiology, and operation departments undertook all possible measures through close cooperation to ensure a safe surgery for the patient with a rare condition.

1 January 2019 in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
Verified
Journal Article
Open access
PDF file
AAAkiko Arimura
Akiko Arimura
HKHiroshi Kono
Hiroshi Kono
MOMasayuki Okido
Masayuki Okido
JMJunichi Motoshita
Junichi Motoshita
YFYasuyoshi Fukami
Yasuyoshi Fukami
症例は53歳,女性.皮膚浸潤・壊死潰瘍を伴う20cmの右乳癌の精査加療目的で受診した.遠隔転移はなかったが腋窩リンパ節転移を伴っていた.血液検査ではWBC 47,200/μLと異常高値を認めたが,炎症所見に乏しかったため血清G-CSFを測定したところ,異常高値であった.局所進行乳癌のため化学療法を開始したが,腫瘍からの出血,蛋白漏出のため継続困難となり,局所制御およびQOLの改善目的に原発巣切除およびリンパ節郭清を行った.病理所見ではHER2蛋白過剰発現と抗G-CSF抗体染色陽性の骨・軟骨化生を伴う乳癌であった.G-CSF産生乳癌は生物学的悪性度が高く予後不良である.HER2が過剰発現し骨・軟骨化生を伴うG-CSF産生乳癌は,本症例が初めての報告である.